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Abstract
A case-control study was conducted to describe the frequency with which structural- and 
individual-level barriers to adherence are experienced by people receiving antiretroviral (ARV) 
treatment and to determine predictors of nonadherence. Three hundred adherent and 300 non-
adherent patients from 6 clinics in Cape Town completed the LifeWindows Information-
Motivation-Behavioral Skills ART Adherence Questionnaire, the Substance Abuse and Mental 
Illness Symptoms Screener and the Structural Barriers to Clinic Attendance (SBCA) and 
Medication-taking (SBMT) scales. Overall, information-related barriers were reported most 
frequently followed by motivation and behaviour skill defects. Structural barriers were reported 
least frequently. Logistic regression analyses revealed that gender, behaviour skill deficit scores, 
SBCA scores and SBMT scores predicted non-adherence. Despite the experience of structural 
barriers being reported least frequently, structural barriers to medication-taking had the greatest 
impact on adherence (OR: 2.32, 95% CI: 1.73 to 3.12), followed by structural barriers to clinic 
attendance (OR: 2.06, 95% CI: 1.58 to 2.69) and behaviour skill deficits (OR: 1.34, 95% CI: 1.05 
to 1.71). Our data indicate the need for policy directed at the creation of a health-enabling 
environment that would enhance the likelihood of adherence among antiretroviral therapy users. 
Specifically, patient empowerment strategies aimed at increasing treatment literacy and 
management skills should be strengthened. Attempts to reduce structural barriers to antiretroviral 
treatment adherence should be expanded to include increased access to mental health care services 
and nutrition support.
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Introduction
With an estimated 5.6 million people infected with HIV, South Africa has one of the highest 
burdens of HIV in the world [1]. Since 2004 when antiretroviral therapy (ART) became 
available in the public sector, South Africa’s national antiretroviral (ARV) treatment 
programme has been rapidly scaled up and an estimated 1.8 million people are currently 
receiving treatment [2]. Not only are the benefits of ART for individuals well-established, 
but the large scale provision of ARV treatment has the potential to result in population-level 
reductions in the transmission of HIV [3, 4]. Adherence is the most important predictor of 
effective viral suppression and treatment [5–7], thus monitoring and support for adherence 
are critical components of any ARV treatment programme [8, 9].
Numerous (mostly qualitative) studies conducted in sub-Saharan Africa (SSA) have 
identified factors that challenge the ability of individuals to adhere to ARV treatment. 
Individual- level barriers to dose adherence and clinic attendance have been found to include 
forgetfulness [17–23], fear of disclosure [14, 17, 18, 20–25], the experience and fear of side 
effects [14, 21, 23, 26–31], travel/migration [17, 21, 22], use of traditional medicine [17, 26, 
30], alcohol use [24, 25], feeling hopeless or depressed [14, 17, 28] and feeling better on 
treatment [20, 29]. Structural barriers are particularly salient in resource-poor settings where 
social, economic, political and environmental factors can impede individual behaviour to a 
greater extent than in wealthy, industrially developed countries [32]. Indeed, two of the most 
commonly reported barriers to ARV adherence in SSA are food insecurity [e.g., 17–19, 21, 
24, 25, 28, 31, 33, 34, 35] and financial constraints [e.g., 14, 17, 19, 21, 25, 27, 30, 34, 36]. 
Other structural factors reported to impede adherence include a lack of confidentiality and 
poor treatment by clinic staff [18, 26, 34], distance to the clinic [21, 37], drug stock-outs 
[23, 30] and long patient waiting times [27, 29, 34].
Potential barriers to optimal adherence are thus well known, but few studies have measured 
the impact of these on adherence. Understanding the determinants of adherence is important 
for ensuring that interventions are designed and implemented to support ART adherence. 
The present study was conducted to investigate barriers to adherence among people on ARV 
treatment in Cape Town, South Africa. Specifically, we aimed to compare the frequency of 
individual-level barriers to structural- level barriers and to identify the significant predictors 
of non-adherence.
Methods
Study design and setting
We conducted a case-control study with 600 adult patients from 6 primary health care ARV 
clinics in the Cape Town metropolitan area. During data collection, these clinics were 
providing free ARV treatment for between 1147 and 2343 adult patients (Western Cape 
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Department of Health, unpublished data). Strategies to support ARV adherence in all 
primary health care clinics in the Western Cape included the provision of individual 
counselling and the roll-out of “adherence clubs” (Medicines Sans Frontiers, 2012). 
Individual counselling was delivered by clinic-based lay counsellors who prepared patients 
to initiate ART during three counselling sessions in which information relating to HIV, 
ARVs and adherence was delivered. Following treatment initiation, patients identified as 
non-adherent by clinic staff were referred for follow-up adherence counselling. Adherence 
clubs are groups of up to 30 patients who are clinically well and adherent to treatment [40]. 
These groups meet in clinics or other communal spaces (including patient’s homes) for a 
quick clinical assessment and to receive pre-packaged treatment for two months. Clubs offer 
peer support and save time and money spent travelling and queuing at clinics [40]. At the 
time of the study, 4 of the 6 participating clinics had an adherence club programme.
Participants and sampling
Participants included roughly equal numbers of adherent and non-adherent patients who had 
been on ART for a minimum of 1 month from each of the six participating clinics. 
Participants were not matched. Patients were identified as dose or programme non-adherent 
by nursing staff as per routine practice, i.e., by means of pill counts (<95% of doses taken 
since last pharmacy refill) or scheduled clinic-visit dates (>3 days late). Patients who were 
≥15 days late were referred to by clinic staff as “returned defaulters”. Systematic random 
sampling was utilised to recruit adherent patients in to the study, whereby every fifth patient 
was approached and invited to take part. Because fewer patients are non-adherent, all those 
identified as non-adherent were approached and invited to take part. Recruitment continued 
until 300 adherent and 300 non-adherent patients had been recruited. The sample size was 
calculated for the comparison of the prevalence of structural barriers reported by adherent 
and non-adherent patients, and to allow us to detect a significant odds ratio of 1.6 with 80% 
power at a 5% significance level.
Data collection
Data collection took place in clinics over a 4-month period (February–June 2012). Data 
collectors obtained participants’ date of treatment initiation and last viral load count from 
their folders; viral load data were collected as a measure that could be used to confirm 
participants’ adherence status. Participants completed a questionnaire by audio computer-
assisted self-interview during regular scheduled visits. The questionnaire was administered 
in English and Xhosa and included questions on demographic characteristics as well as the 
following scales:
The LifeWindows Information-Motivation-Behavioral Skills ART Adherence 
Questionnaire (LW-IMB-AAQ)—The LW-IMB-AAQ (The LifeWindows Project Team, 
2006) is a 33-item measure based on the Information-Motivation-Behavioural Skills (IMB) 
model of health risk behaviour. (We divided one information item into two separate items, 
for a total of 34 items.) In this model, health risk behaviour is understood as the result of 
information, motivation and/or behaviour skills deficits (Fisher & Fisher, 1992). Information 
items assess know- ledge regarding the impact of ART, sub-optimal adherence, traditional 
medicine and alcohol use on treatment efficacy, and what to do in the event of a dose being 
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missed or when there is no food to take treatment with. Items on the Motivation sub-scale 
assess attitudes around the burden of adherence and its impact on daily life, social support 
and the nature of the patient–provider relationship. The Behaviour Skills sub-scale assesses 
self-efficacy in terms of ability to manage adherence in the context of side effects, daily life 
and health status. Cronbach’s alpha was used to determine the reliability of all scales used in 
our sample. The reliability of the Information sub-scale in this sample was poor (α = 0.57). 
Items measuring Behavioural Skill barriers had excellent reliability (α =0.88). The 
Motivation sub-scale had acceptable reliability (α = 0.73).
Structural Barriers to Clinic Attendance Scale (SBCA)—The SBCA and the 
Structural Barriers to Medication- taking scale (below) were developed by Coetzee and 
Kagee (2013) based on qualitative work around structural barriers to ARV adherence in the 
Western Cape. The SBCA scale consists of 12 items that ask the participant to identify the 
extent to which various structural barriers have affected their clinic attendance. Items pertain 
to transport difficulties, work-related commitments, patients’ experiences at the clinic and a 
fear of being identified as HIV-positive by others. We added a time frame of 6 months to 
each item, and 3 items relating to travel between provinces, internationally and for work. 
Participants respond to items on a 5-point Likert scale (“never” to “always”). The reliability 
of this measure in our sample was excellent (α = 0.90).
Structural barriers to medication-taking scale (SBMT)—The SBMT scale consisted 
of 17 items which ask the participant to identify the extent to which various structural 
barriers have affected their medication-taking (since this study the SBMT has been reduced 
to 13 items) (Coetzee & Kagee, 2013). Items pertain to food insecurity, non-disclosure of 
HIV status, the influence of church leaders and traditional healers, alcohol use, the disability 
grant as disincentive to adhere and not having a way to remember to take ARVs. The 
reliability of this measure in our sample was good (α = 0.84).
Substance Abuse and Mental Illness Screener (SAMISS)—The SAMISS consists 
of 16 items and was developed to screen for substance abuse and mental illness (depression, 
anxiety, post-traumatic stress disorder, mania associated with bipolar disorder) in people 
living with HIV [43]. The reliability of items measuring substance abuse in our sample was 
questionable (α = 0.64), while items measuring metal illness had excellent reliability (α = 
0.87).
Statistical analysis
Tests of association, accounting for the clustering of patients within clinics, were done to 
test for significant differences between adherence groups on demographic variables.
To determine the frequency with which participants reported the various barriers, responses 
for each item were dichotomised based on guidance given in the LW- IMB-AAQ (The 
LifeWindows Project Team, 2006) and on the researchers’ choice for the SBCA and SBMT 
scales: “never” and “rarely” were taken to represent no barrier, while “some of the time”, 
“most of the time” and “always” were taken to indicate the presence of a barrier. The 
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frequency with which structural and individual-level barriers were reported was calculated 
overall and by group.
Cronbach’s alpha was calculated for the structural, information, motivation and behavioural 
skills scales as well as for the SAMISS. The reliability of the information sub-scale in this 
sample was improved by removing 3 items, although it remained questionable at 0.67. 
Removing 2 items from the motivation sub-scale and 1 from the behaviour skills sub-scale 
improved internal consistency to .77 and .89 respectively. Based on the internal 
consistencies of the scales, composite scores were calculated for each participant. Based on 
the SAMISS responses, a variable indicating a positive screen for substance abuse or mental 
illness was created. The composite scores and the SAMISS indicator were included as 
predictors in conditional logistic regression models to identify the barriers associated with 
ARV adherence. Gender was included as a covariate, and the observations were grouped by 
clinic. Conditional logistic regression models were fitted in which ARV adherence was 
regressed on gender and each score separately. A conditional logistic regression model was 
also fitted to ARV adherence on all five composite scores, gender and the SAMISS 
indicator. Analyses were conducted using Stata (version 12.1, College Station, TX, USA).
Ethical review
Ethical approval for all study procedures was granted by the Human Research Ethics 
Committee at the University of Cape Town, South Africa.
Results
In total, 622 people were approached to take part. Twenty-two people (12 adherent and 10 
non-adherent) declined to take part. Reasons for refusal included being in a hurry and/or late 
for work, and a lack of interest. Demographic data was not collected for these people.
Of the non-adherent participants, 92 (31%) were on time or ≤3 days late for their scheduled 
clinic visit (they were thus non-adherent by virtue of their pill counts). Seventy-one non-
adherent participants (24%) were >3 but ≤14 days late. The remaining non-adherent 
participants (n = 137, 46%) were “returned defaulters”, having been ≥15 days (maximum 
167) late. In terms of the characteristics of the sample presented in Table 1, employment 
status (p = .032), annual income (p = .028), first language (p = .010) and screening positive 
for mental illness or substance abuse (p = .028) were significantly associated with non- 
adherence.
Overall, information-related barriers were reported most frequently, with the majority of 
barriers being endorsed by more than 50% of participants (range: 0.09 – 0.75). Motivation 
deficits were reported with the second greatest frequency (range: 0.16 – 0.50) followed by 
behaviour skill deficits (range: 0.17 – 0.43). Structural barriers were reported with the least 
frequency. All items on the SBCA and the SBMT, with the exception of two relating to food 
insecurity, were reported by 25% or fewer of the participants.. Barriers relating to food 
insecurity included not always having food to take ARVs with, and feeling ill when taking 
ARVs without food. These barriers were reported with by 37% (95% CI: 28 – 46%) and 
40% (95% CI: 31 – 48%) of the participants respectively.
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The linear range of the scores was determined through exploratory analysis (i.e., lowess 
graphs). A highest attainable value of 6 and 10 was set for the SBCA and SBMT scores 
respectively, and these ranges were utilised in further analyses (Table 2).
When modelled individually, SBCA, SBMT, Information, Motivation and Behavioural 
Skills scores were found to be significantly associated with ARV non-adherence. The result 
of the conditional logistic regression model with all predictors included is shown in Table 3. 
Gender (OR: 2.13, 95% CI: 1.37 to 3.30, p = .001), SBCA (OR: 1.39, 95% CI: 1.23 to 1.56, 
p = <.001), SBMT (OR: 1.38, 95% CI: 1.23 to 1.54, p = <.001) and Behavioural Skills (OR: 
1.08, 95% CI: 1.01 to 1.15, p = .032) were significantly associated with non-adherence. 
Males were 2.13 times more likely to be non-adherent in comparison to females. There was 
no difference between sites in terms of the odds of poor adherence.
Using standardised regression coefficients, the effects of each scale on ARV adherence can 
be compared (Table 4). Results indicate that barriers measured by the SBMT had the 
greatest impact on adherence: one standard deviation increase in the SBMT scale increases 
the odds of being non-adherent by 2.32 (95% CI: 1.73 to 3.12). This is greater than the 
increase in odds associated with a one standard deviation increase in the SBCA scale (OR: 
2.06, 95% CI: 1.58 to 2.69) and the Behavioural Skills scale (OR: 1.34, 95% CI: 1.05 to 
1.71).
Discussion
In South Africa, efforts to expand access to ART have included the decentralisation of ART 
to primary healthcare clinics and the provision of free ARVs for life at these centres. In the 
Western Cape province, the roll-out of adherence clubs further addresses barriers to access 
and adherence by providing easier and quicker access to continued treatment, and reducing 
the frequency and time spent by patients at clinic visits [40]. As the national ARV treatment 
programme continues to grow, it is important to understand the barriers to adherence faced 
by people on treatment so that the programme may continue to respond with interventions 
that meet the needs of recipients. Our study is one of the first to determine the relative 
frequencies with which individual- and structural-level barriers impede adherence, and to 
quantify the impact of these barriers on adherence to ART in SSA.
In this preliminary investigation in to the kinds of barriers impacting ARV adherence in 
Cape Town, we found that adherence-related information deficits were common among all 
participants in this study, although not significantly associated with poor adherence. 
Previous research suggests that increased knowledge does not lead to behaviour change on 
its own (Kalichman, Cain, Eaton, Jooste, & Simbayi, 2011). Nevertheless, people on chronic 
medication should understand their treatment and the implications of sub-optimal adherence. 
Counselling delivered by lay counsellors in preparation for treatment initiation in the 
Western Cape is intended to empower patients towards self-management of their condition 
through treatment literacy. An evaluation of the content and delivery of these sessions, as 
well as patients knowledge immediately following these sessions, may be of value in 
identifying ways to ensure that patients emerge from treatment initiation counselling 
adequately informed about ART.
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Behaviour skill deficits were significantly associated with non-adherence, suggesting that 
people on ART would benefit from assistance in problem-solving and actively managing 
barriers to optimal adherence. The adherence counselling programme within all ARV clinics 
in the Western Cape is intended for this purpose, however previous research indicates that 
adherence counselling consists mainly of the provision of information and advice [44]. 
There is little evidence to suggest that this is an effective way in which to promote 
medication adherence. In contrast, interventions that target practical medication 
management skills have proved to be among the more successful in terms of ARV 
adherence outcomes [45]. The ARV adherence counselling programme, already in place, has 
the potential to address behaviour skill deficits as well as low levels of knowledge regarding 
ART. Strengthening activities may be necessary.
In contrast to barriers associated with IMB constructs, structural barriers were least 
commonly reported but had the greatest impact on adherence. Data from this study supports 
findings from previous qualitative work suggesting food insecurity as a primary barrier to 
adherence in SSA settings. Food insecurity was significantly associated with non-adherence, 
and constitutes a threat to adherence for those who are currently managing optimal 
adherence [e.g., 19, 35]. Thirty-seven percent of all participants in the current study reported 
not always having food with which to take their ARVs. This is consistent with estimates that 
up to one-third of South Africa’s population is food insecure [46]. While patients are not 
necessarily advised that they need to take ARVs with food, some (as in the current study) 
report feeling ill when taking ARVs in the absence of food. Other ways in which food 
insecurity can undermine adherence include competing demands between the cost of 
obtaining food and the cost of attending clinic, and the experience (or fear) of increased 
appetite when on treatment [31, 33, 35]. Evidence regarding the effectiveness of food 
support for improving ARV adherence is limited. A review of the characteristics of HIV 
treatment programmes in 7 SSA countries has shown that the provision of food support is 
not associated with retention in care [47]. Among patients who are retained in care though, 
there is some evidence to suggest that medication adherence is higher in those programmes 
that offer food support [48, 49].
A high percentage of participants in this study screened positive for either substance abuse 
or mental illness, and this was significantly associated with non-adherence. This is 
consistent with previous research and a systematic review of studies in SSA which found 
that the likelihood of achieving good adherence was 55% lower among people with 
depressive symptoms compared to those without [50]. Inadequate services exist for the 
diagnosis, treatment and management of mental health problems in many SSA countries 
[32] including South Africa. In terms of depression, current research is focusing on the 
feasibility of using brief tools [e.g., 51, 52] and community health workers [manuscript 
being prepared for publication] to screen for depression in the context of antenatal care. This 
research could be extended to focus on HIV care, and should be accompanied by attempts to 
improve access to mental health care.
Limitations to this study include the use of clinic staff to refer patients for recruitment by 
data collectors. Primary health care clinics in South Africa are over-burdened and under-
staffed, and data collectors reported cases in which patients were not referred for recruitment 
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because staff were too busy and/or forgot. Randomisation was thus likely compromised. 
Another limitation to this study (and other similar studies) is that the categorisation of 
participants as “adherent” or “non-adherent” is somewhat arbitrary because adherence status 
is not necessarily stable over time. Some people classified and interviewed as “adherent” 
during one month of our study might have been classified and interviewed as “non-
adherent” the next, and vice versa.
Contradictory results from studies evaluating the efficacy of adherence interventions in SSA 
settings suggest that intervention content and/or context are important for intervention 
success [53]. Despite the above-mentioned limitations, this study provides valuable 
information regarding the factors impacting adherence in urban ARV clinics in the Western 
Cape that can be used to guide future research and the development and/or implementation 
of adherence interventions. Our data suggests that patient empowerment strategies aimed at 
increasing treatment literacy and management skills are likely of benefit to people attending 
HIV care at these centres. Attempts to reduce structural barriers to adherence should be 
expanded to include increased access to mental health care services and nutrition support.
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Table 1
Demographic characteristics of participants by adherence status.
Adherent n = 300 Non-adherent n = 300 p-values
Age (mean years) (SD) 36.4 (8.2) 35.3 (9.1) .387
Gender: n (%) .100
   Male 76 (25) 104 (35)
   Female 224 (75) 196 (65)
Marital status: n (%) .064
   Single/widowed/separated/divorced 218 (73) 236 (79)
   Married or living with a significant other in a marriage-like relationship 82 (27) 64 (21)
Living situation: n (%) .872
   Live alone 82 (27) 83 (28)
   Live with other adults and/or children 218 (73) 217 (72)
Education: n (%) .461
   No formal education 33 (11) 44 (15)
   Primary (Grades 1–7) 59 (20) 74 (25)
   Attended/completed secondary school 191 (64) 168 (56)
   Attended/completed tertiary education 17 (6) 14 (5)
Work situation: n (%) .032*
   Employed full-time 62 (21) 39 (13)
   Employed part-time 58 (19) 60 (20)
   Unemployed 163 (54) 182 (61)
   Other (home-maker, disabled, student) 17 (6) 19 (6)
Annual incomea: n (%) .028*
   <R12,000 per year 228 (76) 243 (81)
   R12,000–R40,000 32 (11) 12 (4)
   R41,000–R80,000 10 (3) 2 (1)
   R81,000 and above 13 (4) 8 (3)
First (or home) language: n (%) .010*
   Xhosa 233 (78) 219 (73)
   Afrikaans 18 (6) 33 (11)
   English 20 (7) 12 (4)
   Other 29 (9) 36 (12)
SAMISS indicator: n (%) .028*
   Yes 204 (68) 250 (83)
   No 93 (31) 48 (16)
   Missing data 3 (1) 2 (1)
   Time on ARVs: days (median IQR) 525 (227,1090) 670 (276,1156) .117
Viral loadb .149
   <50 copies/ml 187 (62) 121(40)
   ≥50 copies/ml 61 (20) 117 (39)
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Adherent n = 300 Non-adherent n = 300 p-values
   Missing data 52 (17) 62 (21)
a
ZAR8 = approx. US$1;
b
A viral load of <50 copies/ml is currently regarded as the optimal outcome of ART; 
*
p< .05. Source: Doyle et al., 2012.
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Table 3
Conditional logistic regression of adherence status on gender, mental health, structural barrier and 











Gender (male) 2.13 1.37 3.30 .001*
SAMISS (positive) 1.02 0.63 1.65 .942
SBCA score 1.39 1.23 1.56 <.001*
SBMT score 1.38 1.23 1.54 <.001*
Information score 1.12 0.98 1.28 .085
Motivation score 1.01 0.93 1.11 .770
Behavioural Skills score 1.08 1.01 1.15 .017*
*
p < .05.
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